Concomitant Administration of Dantrolene is Sufficient to Protect Against Doxorubicin-Induced Cardiomyopathy
Short-term concomitant use of dantrolene offers a promising and clinically feasible strategy to prevent DIC. Given dantrolene's established clinical safety as a treatment for malignant hyperthermia, these findings suggest potential for repositioning dantrolene in DIC prevention.
Authors
- Shigeki Kobayashi (ORCID: https://orcid.org/0000-0001-5407-2999)
- Masafumi Yano (ORCID: https://orcid.org/0000-0002-3268-9215)
- Takeshi Suetomi (ORCID: https://orcid.org/0000-0002-5257-9865)
- Motoaki Sano (ORCID: https://orcid.org/0000-0003-1771-8310)
- Tetsuro Oda (ORCID: https://orcid.org/0000-0003-3307-1000)
- Takeshi Yamamoto (ORCID: https://orcid.org/0000-0002-0525-6481)
- Yoshihide Nakamura (ORCID: https://orcid.org/0009-0007-4180-5509)
- Hitoshi Uchinoumi (ORCID: https://orcid.org/0000-0002-5704-3576)
Institutions
- Yamaguchi University (JP)
Publication Details
- Journal
- JACC CardioOncology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1016/j.jaccao.2024.10.011
- Citations
- 15
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 6.03
Funders
- Shinnihon Foundation of Advanced Medical Treatment Research
- Ube Foundation